Clinical trials: Blood
Hemorrhage, Surgical, Blood Loss, Surgical
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent…
- Conditions
- Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
- Trial name
- STAR-T (NCT04976530)
- Testing
- DrugSorb-ATR system
- Where
- 29 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- CytoSorbents, Inc
Cardiovascular Diseases
Use of the Quantra QPlus Sytem in Cardiac Surgery
Single center retrospective study evaluating the impact of using the Quantra QPlus System to guide transfusion decisions on postoperative outcomes in patients undergoing cardiac surgery.
- Trial name
- NCT05501730
- Testing
- Quantra QPlus System
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- HemoSonics LLC
Acute Anemia
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
In this open-label study, eligible and consenting adult patients admitted to the hospital for critical care that have acute severe anemia, defined as a blood hemoglobin level ≤ 5 g/dL, but who are unwilling or unable to receive…
- Trial name
- NCT02754999
- Testing
- SANGUINATE™
- Where
- 32 sites in United States
- Volunteers
- 103 people
- Sponsor
- Prolong Pharmaceuticals
Polycythemia Vera
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia…
- Trial name
- NCT01901432
- Testing
- Givinostat
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 48 people
- Sponsor
- Italfarmaco
Healthy
A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
The main objective of this trial is to investigate the relative bioavailability of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1358894 (Test 1, Test 2) following oral…
- Trial name
- NCT04099732
- Testing
- Rosuvastatin, BI 1358894, Dabigatran etexilate
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give saquinavir (as a soft gel capsule taken by mouth) along with 2 other anti-HIV drugs to HIV-infected patients.
- Trial name
- NCT00002229
- Testing
- Saquinavir
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection, Genotype 1
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.
- Trial name
- NCT01194037
- Testing
- recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- HanAll BioPharma Co., Ltd.
COVID-19, HIV Infections
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected
Evaluation of immunogenicity, safety and persistence of the subjects with HIV infected received the third dose of inactivated COVID-19 vaccine .
- Trial name
- NCT05105295
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Chronic Hepatitis B Virus Infection
A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EDP-721 in healthy subjects.
- Trial name
- NCT04971512
- Testing
- EDP-721, EDP-721 (Part 2), EDP-514
- Where
- New Zealand
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
HIV Infections
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 ) after multiple doses given orally to asymptomatic HIV-1 positive patients who are maintained on a stable dose of zidovudine ( AZT ).
- Trial name
- NCT00002312
- Testing
- Delavirdine mesylate, Zidovudine
- Where
- United States
- Sponsor
- Pharmacia and Upjohn
Kaposi's Sarcoma, HIV Positive
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
- Conditions
- Kaposi's Sarcoma, HIV Positive, AIDS
- Trial name
- NCT02029430
- Testing
- 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
Trauma
Registry AutoLog Lipid Removal and Blood Component Characterization
The purpose of this study is to show the success of the AutoLog System in removing lipids to less than 10mg/dl in vivo. The Autolog registry has two objectives: 1.
- Trial name
- NCT01565967
- Where
- 6 sites in Italy, Lithuania and 4 more
- Volunteers
- 199 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hepatitis B
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201
The purpose of this study is to determine the safety and antiviral activity of Clevudine, when retreated to patients previously treated with Clevudine
- Trial name
- NCT00362700
- Testing
- Clevudine
- Where
- 7 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Bukwang Pharmaceutical
Sepsis-Induced Hypotension
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving…
- Trial name
- ESTELLA (NCT06608901)
- Testing
- REGN7544, PB
- Where
- 29 sites in United States, France
- Volunteers
- 76 people
- Sponsor
- Regeneron Pharmaceuticals
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia…
- Trial name
- NCT00002101
- Testing
- Ethambutol hydrochloride, Clarithromycin, Rifabutin
- Where
- 44 sites in United States
- Volunteers
- 450 people
- Sponsor
- Pharmacia
Hemophilia A
Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A
An open-label, single dose pharmacokinetic study of Xyntha (Moroctocog Alfa (AF-CC), Recombinant Factor VIII) in male Chinese subjects with hemophilia A
- Trial name
- NCT02461992
- Testing
- Intravenous infusions of Xyntha
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Pfizer
Atypical Hemolytic Uremic Syndrome(aHUS)
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric and adult patients diagnosed with aHUS who will be treated according…
- Trial name
- NCT06099236
- Where
- 26 sites in China
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Acute Myelogenous Leukemia, Multiple Myeloma
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
- Conditions
- Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma
- Trial name
- (ANSWer) (NCT04014764)
- Testing
- This is a non-interventional study
- Where
- 20 sites in United States, Greece and 1 more
- Volunteers
- 119 people
- Sponsor
- Notable Labs
Candidiasis, Oral, HIV Infections
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.
- Trial name
- NCT00002399
- Testing
- Posaconazole, Fluconazole
- Where
- 53 sites in United States, Argentina and 16 more
- Volunteers
- 500 people
- Sponsor
- Schering-Plough
Von Willebrand Diseases
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months.
- Trial name
- NCT04053699
- Testing
- Von Willebrand Factor-Containing Product
- Where
- 15 sites in United States, Belarus and 6 more
- Volunteers
- 56 people
- Sponsor
- Octapharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.